On June 26, Insilico Medicine fell 5.76% in regular trading, trading at HK$42.66 per share, with turnover of HK$169 million. The decline comes after the stock accumulated gains of nearly 50% from last Wednesday through June 25.

The selloff is driven by a convergence of factors. Approximately 453 million restricted shares, representing 81.25% of total share capital and valued at roughly HK$24.1 billion, are set to exit their lock-up period on June 29. Market concerns over potential concentrated selling by early shareholders are weighing heavily on sentiment. Meanwhile, recent positive catalysts including the SK Biopharmaceuticals collaboration worth up to $2.5 billion and the Rentosertib Phase III clinical trial initiation appear fully priced in following the sharp rally.

On fundamentals, the company reported revenue declining 34.48% year-over-year with a net loss attributable to shareholders of $352 million, indicating no near-term earnings inflection point. The combination of heavy profit-taking at elevated levels and imminent lock-up expiry is creating significant downward pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)